Form 4: ANI Pharmaceuticals Executive Sells Shares Under 10b5-1 Trading Plan

Muthusamy Shanmugam, Head of R&D and COO-Novitium Ops at ANI Pharmaceuticals, sold 12,855 shares of common stock on May 20, 2024, under a pre-arranged trading plan.

Summary

• Muthusamy Shanmugam, a Director and Officer (Head of R&D, COO-Novitium Ops) of ANI Pharmaceuticals Inc., reported a transaction on May 20, 2024.
• Shanmugam sold 12,855 shares of common stock at a weighted average price of $61.81.
• The sale was executed under a Rule 10b5-1 trading plan adopted on November 27, 2023.
• Following the transaction, Shanmugam directly owns 68,652 shares of common stock.
• Shanmugam also indirectly owns 732,620 shares through Esjay LLC and 5,000 shares through SS Pharma LLC, over which he holds voting and dispositive power.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was conducted under a pre-arranged 10b5-1 trading plan, indicating it was likely planned and not necessarily driven by a change in the insider's view of the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It is important to monitor such filings to understand the sentiment of company insiders regarding the company's stock. The use of a 10b5-1 plan suggests the sale was pre-planned and not necessarily indicative of a sudden change in the insider's outlook.

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates